Biostem Technologies (BSEM) Q2 2025 earnings summary

Executive summary

• Net revenue for Q2 2025 was $49.3 million, down 34% year-over-year due to reimbursement uncertainty and increased competition.

• Achieved sixth consecutive quarter of positive adjusted EBITDA and free cash flow, with adjusted EBITDA at $2.5 million for Q2 2025.

• Gross margin reached 98.6% in Q2 2025, up from 95% in Q2 2024, driven by favorable product mix and VENDAJE AC traction.

• Cash position increased to $30.8 million as of June 30, 2025, up from $20.6 million in Q1 and $22.8 million at year-end 2024.

• Appointed Brandon Poe as CFO and completed enrollment in a key clinical trial.

Financial highlights

• Net revenue for Q2 2025 was $49.3 million, down from $74.5 million in Q2 2024, reflecting a 34% decline year-over-year.

• Gross profit was $48.6 million (98.6% margin), up from 95% in Q2 2024, due to product mix and VENDAJE AC.

• Operating expenses decreased to $48.5 million from $61.9 million year-over-year.

• GAAP net loss for Q2 2025 was $0.6 million ($0.03 per share), compared to net income of $6.3 million ($0.39 per share) in Q2 2024.

• Adjusted EBITDA was $2.5 million, down from $10.1 million in the prior year period.

Outlook and guidance

• Early Q3 indicators show positive momentum and improved customer conversions.

• Data readout from the BioREtain clinical trial for diabetic foot ulcers expected in Q4 2025.

• Uplisting to Nasdaq remains a top priority, with audit and Form 10 amendment in progress.

• Strategic focus on larger mobile wound care providers and expansion of commercial footprint expected to drive durable revenue.

• Ongoing engagement with CMS and industry stakeholders to shape reimbursement policy.